SCHEMBL4792276

SCHEMBL4792276

[CH2]Cn1c(C)nc2c(Oc3ccccc3)nc(C)c(C)c21

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.35
HTT P42858 2/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
TP53 P04637 1/20 0.33
RPS6KA5 O75582 1/20 0.32
KMT2A Q03164 2/20 0.32
TLR7 Q9NYK1 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MRGPRX1 Q96LB2 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4793644 0.85 ALDH1A1 (0.35) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL4795253 0.84 ALDH1A1 (0.51) LMNAHTTALDH1A1TP53SMN1; SMN2
SCHEMBL4793826 0.81 LMNA (0.39) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL4791598 0.80 ALDH1A1 (0.37) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL5337848 0.79 SLC18A3 (0.37) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL4793186 0.77 LMNA (0.37) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL6670204 0.76 CYP1A2 (0.35) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL4793987 0.76 TP53 (0.32) TP53KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL4793912 0.76 SLC18A3 (0.35) LMNAHTTALDH1A1CYP1A2CYP2C19
SCHEMBL6094297 0.76 TLR7 (0.43) LMNAHTTALDH1A1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513524-A4 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2008-09-03 EP disclosed
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
EP-1513524-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2005-03-16 EP disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed
WO-2003103584-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 LMNA 4400/4885HTT 4588/4885ALDH1A1 1803/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP LMNA 4818/4885HTT 4440/4885ALDH1A1 940/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 LMNA 4400/4885HTT 4588/4885ALDH1A1 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.